Regorafenib is introduced under the brand name Stivarga. It is mainly an oral multi-kinase inhibitor that targets angiogenic, stromal, and oncogenic RTK. The medical approval of regorafenib includes Metastatic colorectal cancer, Advanced gastrointestinal stromal tumors, and advanced hepatocellular carcinoma. Regorafenib represents the anti-angiogenic activity because of its dual-targeted VEGFR2-TIE2 tyrosine kinase inhibition. This drug is being approved with a Boxed Warning alerting patients and health specialists that fatal liver toxicity may occur in recipients treated with regorafenib during clinical studies.